Skip to main content

2017 Second Annual Oncology Guide to New FDA Approvals

FDA Updates
Welcome to the Second Annual Oncology Pharmacy Guide to New FDA Approvals
Read More
FDA Updates
FDA Approvals of Brand-Name Prescription Drugs in 2016
Read More
FDA Updates
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala, Medical Writer
Read More
FDA Updates
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Tecentriq (Atezolizumab), PD-L1 Inhibitor, Approved for Advanced Bladder Cancer and for Relapsed Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Venetoclax
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More

Results 1 - 8 of 8